UTY
Overview
UTY (Ubiquitously Transcribed Tetratricopeptide Repeat Containing, Y-Linked) is the Y-chromosome paralog of KDM6A (UTX), encoding a histone H3K27 demethylase. In bladder/transitional cell carcinoma (TCC), UTY is altered as part of the broad chromatin-remodeling gene set that accounts for 58% of TCC cases, consistent with frequent KDM6A/UTY axis disruption in urothelial malignancy.
Alterations observed in the corpus
- UTY mutations identified as part of the KDM6A/UTY chromatin-remodeling axis in TCC bladder cancer; alterations across the broader chromatin-remodeling gene set (including KDM6A/UTY, ARID1A/ARID4A, KMT2A/C/E, EP300/EP400, CREBBP, NCOR1, CHD6, SMARCA4, KDM5A/B) total 58% of TCC cases PMID:24121792.
- Recurrent deletion in cholangiocarcinoma (n=17 cases) in the 489-sample multi-omic CCA cohort PMID:28667006
Cancer types (linked)
- BLCA (TCC): UTY mutations contribute to the dominant chromatin-remodeling alteration burden in bladder cancer, which represents the first solid tumor type with a predominant SWI/SNF and cohesin–chromosomal-segregation alteration burden PMID:24121792.
Co-occurrence and mutual exclusivity
- Co-altered with KDM6A (its X-chromosome paralog) and a broad panel of chromatin-remodeling genes (ARID1A, KMT2A/C/E, EP300, CREBBP, SMARCA4) collectively mutated in 58% of TCC PMID:24121792.
Therapeutic relevance
- Chromatin-remodeling gene disruption (including KDM6A/UTY axis) is the most prevalent alteration class in TCC; the therapeutic implications of histone-demethylase loss in bladder cancer have not been directly addressed in this cohort PMID:24121792.
Open questions
- The relative contribution of UTY versus KDM6A mutations to the chromatin-remodeling alteration burden in TCC is not individually quantified in this cohort PMID:24121792.
Sources
This page was processed by crosslinker on 2026-05-09. - PMID:28667006
This page was processed by wiki-cli on 2026-05-15.